Drug intelligence / Profile preview

KK3910

Development stage: Phase 1
Lead developer: Kyowa Kirin
Modality: Small Molecules
Administration: Subcutaneous Injection[1][7]

Overview

KK3910 is a novel antihypertensive drug candidate being developed by Kyowa Kirin for the treatment of essential hypertension. It is classified as a new molecular entity and is currently in early clinical development, with phase 1 trials initiated in Japan as of April 2025. The precise mechanism of action for KK3910 has not been disclosed or defined publicly. The drug is administered via subcutaneous injection and represents an investigational approach to managing high blood pressure[1][2][3][4][5][7].

Beyond the preview

Go deeper on KK3910.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KK3910.

Explore the full profile